Tirzepatide: Dual GIP/GLP-1 Receptor Agonists, from Molecular to Clinical Practice for Treating Type-2 Diabetes and Obesity. InaJEMD. 2024;1(2):96-110. Accessed August 3, 2025. https://inajemd.pbperkeni.or.id/index.php/journal/article/view/vol1-no2-section12